【雅塑youngsure是哪个国家的品牌？】

外推网助力雅塑youngsure品牌出海！通过在本页面挂载雅塑youngsure品牌的产品链接和联系邮箱，可以提高雅塑youngsure产品曝光！跨境电商爆单神器，目前只要100元/年哦~

重庆植恩药业有限公司创办于2001年，是立足于重庆的一家集研发、生产和销售一体化的新兴医药企业，是一家集两江药物研发中心、手性工程中心和新药设计工程中心等三大研发中心、原料药生产基地、制剂生产基地和销售总部的集团公司。

植恩药业高度重视研发和创新，并已具备了很强的研发能力。公司的两江药物研发中心为重庆市唯一的国家级“药物先进制造技术国家地方联合工程研究中心”，手性工程中心和新药设计工程中心均为重庆市级工程中心，公司还设有重庆市级博士后流动站，为公司提供持续的高级人才储备。经过多年的努力，公司已经获得新药证书33项、临床批件32项、生产批件51项；申请国家发明专利数十项，其中已获国外专利授权2件，国内专利授权12件。公司已开展研发项目32项，承担包括国家重大新药创制项目（“11.5”和“12.5”）等70余项各类课题，并获得全国及省级奖项数十项。目前在研项目涉及神经系统药物、代谢系统药物、消化系统药物及其他类药物，其中神经系统药物已成为公司发展的主要方向，其中包括化药1类新药2项、中药5类新药1项。

植恩药业产业化能力较强，产能正逐步扩大。现有原料药生产基地年生产能力超过40吨，新建82000平方原料药生产基地将使产能提高到每年60吨-80吨，核心API品种奥利司他质量及产能达到国际先进水平，产品已热销巴西、澳大利亚、德国、波兰、新加坡和韩国，且已经在美国和印度递交上市申请，未来国际市场将进一步拓宽。现有制剂生产线可生产胶囊剂、颗粒剂、片剂、栓剂等剂型，在建制剂生产线将新增冻干剂型、小/大容量注射液等剂型，在建制剂产业化基地建筑面积33330㎡。

公司产品丰富，后续产品充足。目前主打产品有奥利司他、盐酸多奈哌齐、盐酸罗匹尼罗、甲磺司特等，即将上市的重点产品包括盐酸他利克索和盐酸兰地洛尔等。

植恩药业具有强大的一级市场到达终端市场的分销商网络。目前拥有零售终端及医院终端销售人员500余人。产品覆盖30个城市2000多家医院，40000家药店。外贸方面，原料药出口到全球20多个国家。

公司以“木直因心，植药为仁”为座右铭，以“创建中国医药与健康服务的领先企业”为发展目标。在强大的医药研发团队、高效的医学注册能力、广泛坚固的医药渠道网络、专业化的市场销售能力、权威的政府事务及专业机构合作能力支持下，立志将公司打造成行业内知名的高新技术医药企业。

英文翻译：Founded in 2001, Chongqing Zhien Pharmaceutical Co., Ltd. is a new pharmaceutical enterprise integrating R & D, production and sales based in Chongqing. It is a group company integrating three R & D centers, API production base, preparation production base and sales headquarters, including Liangjiang pharmaceutical R & D center, chiral Engineering Center and new drug Design Engineering Center. Zhien pharmaceutical attaches great importance to R & D and innovation, and has a strong R & D capability. Liangjiang pharmaceutical R & D center of the company is the only national level "national and local joint engineering research center of advanced pharmaceutical manufacturing technology" in Chongqing. The chirality Engineering Center and new drug design engineering center are both Chongqing Municipal Engineering Center. The company also has Chongqing Municipal Post Doctoral mobile station to provide the company with continuous senior talent reserve. After years of efforts, the company has obtained 33 new drug certificates, 32 clinical approvals and 51 production approvals; applied for dozens of national invention patents, including 2 foreign patent authorizations and 12 domestic patent authorizations. The company has carried out 32 R & D projects, undertaken more than 70 various subjects including national major new drug development projects ("11.5" and "12.5"), and won dozens of national and provincial awards. At present, the research projects involve nervous system drugs, metabolic system drugs, digestive system drugs and other drugs, among which nervous system drugs have become the main development direction of the company, including 2 chemical drugs of class 1 and 1 Traditional Chinese medicine of class 5. The industrialization capacity of Zhien pharmaceutical industry is strong, and the production capacity is gradually expanding. The annual production capacity of the existing API production base is more than 40 tons. The newly built 82000 square meters API production base will increase the production capacity to 60-80 tons per year. The quality and production capacity of the core API variety ollistat reach the international advanced level. The products have been sold well in Brazil, Australia, Germany, Poland, Singapore and South Korea, and have submitted listing applications in the United States and India. In the future, the international market It will be further expanded. The existing preparation production line can produce capsule, granule, tablet, suppository and other dosage forms. The new dosage forms, such as freeze-drying dosage form, small / large volume injection, will be added to the preparation production line under construction. The construction area of the preparation industrialization base under construction is 33330 ㎡. The company has abundant products and sufficient follow-up products. At present, the main products are orlistat, donepezil hydrochloride, ropinirol hydrochloride, mesylate, etc. the key products to be launched include talicosol hydrochloride and randilol hydrochloride, etc. Zhien pharmaceutical has a strong distributor network from primary market to terminal market. At present, it has more than 500 retail terminal and hospital terminal sales personnel. The products cover more than 2000 hospitals and 40000 pharmacies in 30 cities. In terms of foreign trade, APIs are exported to more than 20 countries around the world. The company takes the motto of "wood for heart, planting medicine for humanity" and the development goal of "building a leading enterprise of Chinese medicine and health service". With the support of a strong pharmaceutical R & D team, efficient medical registration ability, extensive and solid pharmaceutical channel network, professional marketing ability, authoritative government affairs and cooperation ability of professional institutions, we are determined to build the company into a well-known high-tech pharmaceutical enterprise in the industry.

本文链接： https://www.waitui.com/brand/918e6e5a8.html 联系电话：请联系客服添加